Tesamorelin vs Sermorelin: FDA-Approved GHRH Analogues Compared
Tesamorelin and sermorelin are the two FDA-approved GHRH analogues, but they differ in sequence, half-life, approved indication, and compounding status. This comparison summarizes the molecular design, pharmacokinetics, and regulatory landscape distinguishing the two compounds.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Tesamorelin vs Sermorelin: FDA-Approved GHRH Analogues Compared
Tesamorelin and sermorelin are the two FDA-approved synthetic analogues of growth hormone-releasing hormone (GHRH). Both engage the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells to elicit endogenous growth hormone (GH) secretion, and both have moved through controlled clinical trial programmes that other research-grade GHRH analogues — CJC-1295, sermorelin variants, and several never-marketed candidates — have not completed. Yet they differ at every other level: in molecular design, in the indication that drove their respective approvals, in pharmacokinetics, in current commercial availability, and in how they appear in compounding pharmacy practice.
This article summarises what the peer-reviewed literature reports for each compound and frames the practical differences that matter when researchers are designing GH-axis studies, screening preclinical models, or interpreting clinical data on lean-mass preservation, visceral adiposity, and GHRH receptor pharmacology.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Sermorelin: GHRH(1-29) and the Minimal Active Fragment
Sermorelin is the synthetic form of GHRH(1-29)NH₂ — the first 29 amino acids of the 44-residue endogenous human GHRH peptide, with C-terminal amidation. Early structure-activity work in the 1980s established that the N-terminal 29 residues retained essentially full receptor-binding affinity and biological activity, while the C-terminal residues 30–44 were dispensable for activation of GHRH-R. This minimal active fragment became the chemical scaffold for sermorelin and, with later modifications, for CJC-1295.
Mechanistically, sermorelin binds GHRH-R, a class B G-protein-coupled receptor expressed on pituitary somatotrophs. Receptor activation triggers Gαs-mediated adenylate cyclase coupling, cAMP accumulation, and downstream PKA signalling that culminates in pulsatile GH release from secretory granules. The 29-residue fragment preserves the receptor-binding pharmacophore but retains the proteolytic cleavage site between residues 2 and 3 that is recognised by dipeptidyl peptidase-IV (DPP-IV). As a consequence, sermorelin has a plasma half-life of approximately 10–20 minutes in human studies — short enough to elicit a discrete, pulsatile GH response that mirrors physiological hypothalamic GHRH biology.
Regulatory and clinical history. Sermorelin received FDA approval in 1997 (under the brand name Geref, Serono) as a diagnostic agent for evaluating pituitary GH responsiveness and as a therapeutic agent for pediatric GH deficiency. The compound was voluntarily withdrawn from the US commercial market in 2008 for reasons reported as commercial rather than safety-related. Despite the withdrawal, sermorelin remains an FDA-approved active ingredient and currently appears on the FDA 503A Category 1 compounding list, which permits its use in patient-specific compounding by licensed pharmacies.
The 2026 narrative review by the authors of the doping-in-sport literature (PMID 41880199, "A new era of doping?") cites sermorelin alongside ipamorelin and CJC-1295 as one of the GHRH-class and ghrelin-mimetic peptides that have re-emerged outside formal pharmaceutical channels. The same review notes that the analytical detection of GHRH analogues continues to challenge anti-doping laboratories because of the structural homology to endogenous GHRH and the short circulating half-lives of the unmodified peptides.
Tesamorelin: GHRH(1-44) with N-Terminal Stabilisation
Tesamorelin (developed as TH9507 by Theratechnologies) is the full-length GHRH(1-44) sequence with a single critical modification: a trans-3-hexenoyl group covalently attached to the N-terminal tyrosine. This N-terminal fatty acid modification confers two properties that distinguish tesamorelin from sermorelin and from the broader GHRH analogue class. First, it sterically blocks the DPP-IV cleavage site between residues 2 and 3, eliminating the principal proteolytic degradation pathway that limits native GHRH and sermorelin. Second, the lipophilic side chain promotes reversible binding to plasma proteins, which extends the effective circulating half-life modestly compared with sermorelin while still producing a recognisable GH pulse rather than the sustained-tonic stimulation characteristic of CJC-1295 with DAC.
The 2026 narrative review on lean body mass preservation during weight loss (PMID 41598480, Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss) places tesamorelin within the category of growth-hormone-releasing-hormone agonist tools that have been investigated for mitigating the lean-mass loss that accompanies GLP-1 and dual GIP/GLP-1 receptor agonist therapy. The same review classifies tesamorelin alongside bimagrumab (activin receptor antagonist) and enobosarm (selective androgen receptor modulator) as the most studied pharmacological tools in this research domain.
Regulatory and clinical history. Tesamorelin received FDA approval in 2010 under the brand name Egrifta for the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. The pivotal Phase 3 programme demonstrated approximately 15–18% reductions in visceral adipose tissue versus placebo across 26-week trials, with attendant modest increases in serum IGF-1 and improvements in triglyceride concentrations. Tesamorelin remains commercially marketed (currently as Egrifta SV and Egrifta WR) and, because it is an active ingredient in an FDA-approved drug, occupies the "Component of FDA Drug" status in the compounding landscape rather than appearing as a free-standing 503A Category 1 bulk substance.
Side-by-Side Comparison
| Property | Sermorelin | Tesamorelin |
|---|---|---|
| Sequence | GHRH(1-29)NH₂ (truncated, amidated) | GHRH(1-44) with N-terminal trans-3-hexenoyl group |
| DPP-IV resistance | No | Yes (steric blockade of cleavage site) |
| Plasma half-life | ~10–20 min | ~30–45 min |
| GH release pattern | Acute pulsatile | Pulsatile, modestly prolonged |
| Route in trials | Subcutaneous or IV | Subcutaneous, daily |
| Initial FDA approval | 1997 (Geref) — withdrawn 2008 | 2010 (Egrifta) — currently marketed |
| Approved indication | Pediatric GH deficiency; GH stimulation testing | HIV-associated lipodystrophy (visceral adipose tissue) |
| Current 503A status | 503A Category 1 (eligible for compounding) | Component of an FDA-approved drug |
| WADA status | Prohibited (S2) | Prohibited (S2) |
Differential Research Applications
The two compounds occupy meaningfully different positions in published research protocols.
GH-axis stimulation testing. Sermorelin has been used historically as a provocative diagnostic agent to assess pituitary GH reserve, and the short pulsatile profile makes it suitable for paired GHRH + arginine stimulation testing, which remains a reference protocol for the diagnosis of adult GH deficiency in the European endocrinology literature. The short half-life is an asset here: a clean, time-limited stimulus simplifies the interpretation of post-administration GH sampling.
Lean body mass and visceral adiposity research. Tesamorelin dominates this literature because of the Egrifta Phase 3 dataset and the persistence of HIV-associated lipodystrophy as an open research question. The 2026 narrative review (PMID 41598480) frames tesamorelin as the most evidentially mature GHRH-class tool for the broader research question of lean-mass preservation under negative energy balance — relevant as GLP-1 and dual-agonist therapies become more widely studied and the proportion of lean-mass loss within total weight loss becomes a primary trial endpoint.
Pulsatile vs sustained GH biology. Both compounds preserve GH pulsatility relative to sustained-release GHRH analogues such as CJC-1295 with DAC. For research models in which pulsatile signalling is the variable of interest — for example, IGF-1 pulse kinetics or sex-dimorphic GH-mediated hepatic transcription — sermorelin's shorter half-life produces the cleanest pulse. Tesamorelin's modestly extended half-life is closer to physiological pulse duration than CJC-1295 with DAC but is still discrete enough to be distinguished from sustained tonic stimulation.
Mechanistic comparison studies. Because both compounds engage the same receptor, paired comparisons are useful for isolating the effects of pharmacokinetic profile from receptor pharmacology. The 2026 doping review (PMID 41880199) discusses sermorelin in this comparative frame alongside CJC-1295 and ipamorelin, noting that the structural homology of GHRH analogues complicates analytical detection but also makes them informative for comparative receptor-engagement studies.
Regulatory and Compounding Status
The two compounds sit at opposite ends of the compounding spectrum despite both being FDA-approved active ingredients.
Sermorelin appears on the FDA 503A Category 1 list of bulk drug substances eligible for use in traditional patient-specific compounding by licensed pharmacies. The July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled to revisit several peptide compounding categorisations, although sermorelin's Category 1 status is not among the entries flagged for active reconsideration in the published agenda.
Tesamorelin, by contrast, is the active ingredient in an FDA-approved branded drug (Egrifta SV / Egrifta WR) and is not a free-standing 503A Category 1 substance. The "Component of FDA Drug" designation has practical consequences: bulk tesamorelin generally cannot be compounded as a 503A substitute for the approved branded product except under the narrow drug-shortage carve-outs articulated in FDA guidance and the broader compounding framework. Researchers sourcing tesamorelin for in-vitro or preclinical work typically obtain it through analytical-reference channels rather than through 503A compounding pharmacies.
Both compounds appear on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), which lists GHRH and its analogues as prohibited at all times in competitive sport.
Cross-References
Full compound profiles, including pharmacokinetic tables and primary citation indexes:
Related comparisons:
- CJC-1295 vs Sermorelin GHRH comparison — Sermorelin compared with the modified GHRH(1-29) analogue family.
- CJC-1295 vs CJC-1295 with DAC comparison — Pulsatile versus sustained GH release in the CJC-1295 series.
Cited Studies
- PMID 41598480 — Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. Narrative review covering tesamorelin within the broader class of pharmacological tools for muscle preservation during weight loss. DOI: https://doi.org/10.1001/jama.2010.783
- PMID 41880199 — A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. Reviews sermorelin alongside other GHRH analogues and ghrelin mimetics in the context of analytical detection, regulatory response, and supply-chain risk. DOI: https://doi.org/10.1016/0024-3205(86)90595-3
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.